Philips Receives FDA Approval for AI-based Cardiac Surgery Tool
Royal Philips announced in a press release that it has received FDA approval for EchoNavigator R5.0 with DeviceGuide, an artificial intelligence-based software solution designed to assist physicians during complex minimally invasive cardiac valve repair procedures.
Innovative Integration of AI in Cardiac Procedures
DeviceGuide utilizes artificial intelligence to track and visualize mitral valve repair devices in real-time during minimally invasive procedures. The solution is integrated into Philips' Azurion guided imaging platform, which combines imaging, real-time data, and intelligent software into a unified workflow, enabling more consistent, efficient, and confidently performed minimally invasive interventions.
FDA Approval Amid Technically Demanding Cardiology Procedures
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
This FDA approval comes in the context of some of the most technically demanding procedures in interventional cardiology. Philips positions this solution as a support tool for physicians, aligning with its broader strategy in the healthcare and guided imaging technology sectors.
SectorSanté · Technologie · Dispositifs médicaux›Équipements Médicaux
Context
Period
Period: 1T2026
Key reported figures
Revenue: 3.9MD€
Free cash flow: 28M€
Guidance from the release
Nous avons délivré un bon départ en 2026.
Bonne performance au T1, croissance des ventes et des marges.
Risks mentioned
Impact des tarifs et inflation des coûts sur les marges.
Environnement macroéconomique incertain impactant les performances.
Opportunities identified
Croissance des ventes comparables de 4% dans tous les segments.
Augmentation du carnet de commandes grâce à des innovations.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
